NCT03653507 2026-04-17
GLOW
Astellas Pharma Inc
Phase 3 Active not recruiting
Clinical Trials
10 trialsNCT07431281 2026-04-13
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
AstraZeneca
Phase 3 Recruiting
NCT06901531 2026-04-03
LUCERNA
Astellas Pharma Inc
Phase 3 Recruiting
NCT03504397 2026-02-13
Spotlight
Astellas Pharma Inc
Phase 3 Active not recruiting
NCT07385703 2026-02-04
Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Not yet recruiting
NCT03013010 2025-12-08
PREACT
Shanghai Cancer Hospital, China
Phase 3 Completed
NCT07118800 2025-08-12
NACRE-2
UNICANCER
Phase 3 Not yet recruiting
NCT02509286 2024-05-08
ESOPEC
University Hospital Schleswig-Holstein
Phase 3 Active not recruiting
NCT06177041 2024-02-28
M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
FutureGen Biopharmaceutical (Beijing) Co., Ltd
Phase 3 Recruiting
NCT05264896 2023-09-07
Perioperative FLOT vs Adjuvant XELOX for CA Stomach
Chinese University of Hong Kong
Phase 3 Recruiting